Abstract
Mycobacterial lipoproteins are involved in both virulence and immunoregulatory processes during Mycobacterium tuberculosis (M.tb) infection. In previous investigations of over 30 M.tb proteins, mycobacterial lipoprotein Z (LppZ) was identified as a highly immune-dominant antigen. This study explores how LppZ triggers immune responses using murine air pouch and M.tb infection models. Results show that LppZ recruits inflammatory cells and induces proinflammatory cytokines. Furthermore, LppZ immunization induces strong Th1 responses and confers protection against the virulent H37Rv strain at levels comparable to BCG, but with significantly less pathological lung damage. Protection is linked to LppZ-specific polyfunctional CD4<sup>+</sup> T cells capable of secreting IFN-γ, IL-2, and TNF-α. These findings highlight LppZ's strong immunogenicity and its potential as a candidate for TB vaccine development.
Introduction
Tuberculosis (TB) remains a leading cause of death from infectious disease globally. The standard Bacille Calmette-Guérin (BCG) vaccine, while effective in children, shows inconsistent protection against pulmonary TB in adults. The search for novel vaccine candidates is often limited by a narrow focus on a few well-known antigens. This research focuses on LppZ, a protein identified as highly reactive in TB patients, to determine if it can effectively bridge innate and adaptive immune responses to provide superior protection.
Methods
The study employed a multi-stage experimental design:
- Clinical Immunoreactivity: ELISpot assays were used to measure IFN-γ responses to LppZ in 86 TB patients and 48 healthy controls, comparing it to the standard E6C10 (ESAT6-CFP10) antigen.
- Innate Response Modeling: A murine air pouch model was used to observe the immediate recruitment of neutrophils and macrophages and the secretion of cytokines in response to LppZ.
- Vaccination and Challenge: Mice were immunized with recombinant LppZ (adjuvanted with DDA/MPL) and subsequently challenged with aerosolized M.tb H37Rv. Bacterial loads (CFU) and histopathological lung scores were recorded.
- Polyfunctional T-Cell Analysis: Flow cytometry was used to identify CD4+ T cells in the lungs capable of producing multiple cytokines (IFN-γ, IL-2, and TNF-α) simultaneously.
Key Results
LppZ as a Dominant Human Antigen
Clinical data confirmed that LppZ is a primary target for the human immune system during natural infection. LppZ-specific T-cell responses were as robust as those elicited by the gold-standard E6C10 antigen.
As illustrated in Figure 5, LppZ-specific IFN-γ responses effectively discriminated TB patients from healthy controls with an Area Under the Curve (AUC) of 0.8739. This diagnostic performance reached 50% sensitivity and 97.92% specificity, confirming its high immunogenicity in humans.
Protective Efficacy and Reduced Pathology
In mouse models, LppZ demonstrated a unique ability to act as an "innate-adaptive bridge," recruiting inflammatory cells directly. Following challenge with virulent M.tb, LppZ-immunized mice showed a significant reduction in bacterial load (~4.5 Log10 CFU) compared to controls (~5.0 Log10 CFU), approaching the efficacy of BCG (~4.1 Log10 CFU).
Notably, LppZ vaccination resulted in significantly less lung tissue damage than the adjuvant-only control. Pathological scoring indicated that LppZ-mediated immunity is more "surgical," providing protection without the extensive inflammatory consolidation often seen in TB infection.
Induction of Polyfunctional T Cells
The protective effect was associated with the presence of polyfunctional CD4+ T cells in the lungs. These cells, which secrete IFN-γ, IL-2, and TNF-α, are considered the most effective T-cell subset for controlling M.tb infection.
Discussion and Future Directions
LppZ is a potent immunogen that triggers both innate danger signals and high-quality adaptive cellular immunity. Its ability to match BCG's protective levels while minimizing lung pathology makes it a highly attractive candidate for future TB vaccine strategies, potentially as a booster to BCG.
Future research should address the durability of this immune memory and evaluate LppZ's performance across different delivery platforms, such as viral vectors or lipid nanoparticles. Additionally, while the mouse model is informative, further studies in non-human primates may be necessary to better understand LppZ's impact on human-like granuloma formation.
Summary updated